Siemens Fonds Invest GmbH Acquires Shares of 603,115 Organon & Co. (NYSE:OGN)

Siemens Fonds Invest GmbH bought a new stake in shares of Organon & Co. (NYSE:OGN - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 603,115 shares of the company's stock, valued at approximately $8,998,000. Siemens Fonds Invest GmbH owned 0.23% of Organon & Co. as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of OGN. Millstone Evans Group LLC acquired a new stake in Organon & Co. in the 4th quarter valued at $29,000. Larson Financial Group LLC grew its position in Organon & Co. by 345.4% in the 4th quarter. Larson Financial Group LLC now owns 2,236 shares of the company's stock valued at $33,000 after purchasing an additional 1,734 shares during the period. Riverview Trust Co grew its position in Organon & Co. by 117.7% in the 4th quarter. Riverview Trust Co now owns 2,390 shares of the company's stock valued at $36,000 after purchasing an additional 1,292 shares during the period. GeoWealth Management LLC acquired a new stake in Organon & Co. in the 4th quarter valued at $41,000. Finally, WFA Asset Management Corp bought a new position in Organon & Co. during the 4th quarter valued at $68,000. Institutional investors and hedge funds own 77.43% of the company's stock.

Insider Activity at Organon & Co.

In related news, insider Kirke Weaver bought 8,045 shares of Organon & Co. stock in a transaction on Tuesday, May 6th. The stock was acquired at an average price of $9.21 per share, with a total value of $74,094.45. Following the acquisition, the insider now directly owns 52,489 shares of the company's stock, valued at $483,423.69. This represents a 18.10% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel Karp bought 3,500 shares of Organon & Co. stock in a transaction on Tuesday, May 6th. The shares were bought at an average cost of $8.24 per share, with a total value of $28,840.00. Following the acquisition, the vice president now directly owns 46,669 shares in the company, valued at approximately $384,552.56. This represents a 8.11% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have bought 102,345 shares of company stock worth $902,430. Company insiders own 1.96% of the company's stock.

Organon & Co. Stock Performance

Shares of NYSE OGN traded down $0.34 during mid-day trading on Friday, reaching $9.20. 5,303,686 shares of the company's stock were exchanged, compared to its average volume of 3,306,457. The firm has a market capitalization of $2.39 billion, a price-to-earnings ratio of 2.76, a price-to-earnings-growth ratio of 0.90 and a beta of 0.75. Organon & Co. has a 52 week low of $8.01 and a 52 week high of $23.10. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The firm has a 50-day moving average price of $10.92 and a two-hundred day moving average price of $13.82.

Organon & Co. (NYSE:OGN - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $1.02 EPS for the quarter, topping analysts' consensus estimates of $0.89 by $0.13. The company had revenue of $1.51 billion for the quarter, compared to analysts' expectations of $1.53 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The business's revenue for the quarter was down 6.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.22 EPS. Analysts predict that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 12th. Investors of record on Monday, May 12th will be paid a $0.02 dividend. This represents a $0.08 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date is Monday, May 12th. Organon & Co.'s dividend payout ratio is currently 2.78%.

Wall Street Analysts Forecast Growth

OGN has been the topic of several recent analyst reports. Evercore ISI cut Organon & Co. from an "outperform" rating to an "inline" rating in a research note on Friday, May 2nd. Barclays dropped their price objective on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Piper Sandler dropped their price objective on Organon & Co. from $24.00 to $18.00 and set an "overweight" rating on the stock in a research note on Thursday, May 15th. BNP Paribas upgraded Organon & Co. to a "strong-buy" rating in a research note on Thursday, May 22nd. Finally, Morgan Stanley dropped their price objective on Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $18.00.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.